Author: Jasenosky, Luke D.; Cadena, Cristhian; Mire, Chad E.; Borisevich, Viktoriya; Haridas, Viraga; Ranjbar, Shahin; Nambu, Aya; Bavari, Sina; Soloveva, Veronica; Sadukhan, Supriya; Cassell, Gail H.; Geisbert, Thomas W.; Hur, Sun; Goldfeld, Anne E.
Title: The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus Document date: 2019_8_8
ID: yomg30hg_30
Snippet: Finally, the studies presented here suggest that after validation in an in vivo animal model, NTZ could be potentially useful in EBOV disease as monotherapy or as an adjuvant therapy with agents that specifically target EBOV components. Furthermore, NTZ may also prove valuable in strategies to prevent EBOV infection or to eradicate EBOV reservoirs that persist in patients who have survived EBOV disease......
Document: Finally, the studies presented here suggest that after validation in an in vivo animal model, NTZ could be potentially useful in EBOV disease as monotherapy or as an adjuvant therapy with agents that specifically target EBOV components. Furthermore, NTZ may also prove valuable in strategies to prevent EBOV infection or to eradicate EBOV reservoirs that persist in patients who have survived EBOV disease.
Search related documents:
Co phrase search for related documents- adjuvant therapy and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- animal model and EBOV disease: 1
- animal model and EBOV infection: 1, 2, 3
- animal model and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- animal model and vivo animal model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- present study and valuable prove: 1, 2, 3
- present study and vivo animal model: 1, 2, 3
- strategy valuable prove and valuable prove: 1, 2
Co phrase search for related documents, hyperlinks ordered by date